While targeting HK2 holds potential, several challenges need to be addressed:
Selectivity: HK2 is also expressed in some normal tissues, so therapies need to be selective to avoid toxicity and unwanted side effects. Resistance Mechanisms: Cancer cells may develop resistance mechanisms to bypass HK2 inhibition, making combination therapies necessary. Delivery: Efficiently delivering HK2 inhibitors to tumor cells without affecting normal cells remains a significant hurdle.
